Near-Infrared Imaging of Veins in Facial Injection of Botulinum Toxin and Hyaluronic Acid

Guillermo Blugerman, MD,* Diego Schavelzon, MD,* and Julián Álvarez, MD†

The efficacy of the application of botulinum toxin type A (BTX-A) and hyaluronic acid (HA) as minimally invasive treatments in facial rejuvenation has been previously demonstrated.1,2 The local side effects most frequently observed are pain, swelling, erythema, and bruising.1–4 In spite of the limited and benign nature of these events, they usually cause discomfort for the patient who is looking for aesthetic improvement.

Materials and Methods

The Vein Viewer (VV) (Luminetx Corp., Memphis, TN) is a device designed to project the enhanced image of the subcutaneous veins onto the skin. VV operates through near-infrared light emission that is scattered in the skin and subcutaneous fat, while it is partially absorbed in venous blood flow. A camera captures the outcome emission, and the image, processed by computer, is projected onto the skin surface as a green light.5

Optimal performance is achieved when the image is in focus and when the axis of the emission is perpendicular to the surface of the skin. With this technique, not-apparent subcutaneous veins are easily identified. Its use has been described for vascular identification in peripheral venous disease, as adjuvant in venipuncture of children, and in difficult venous access.5,6

We propose the use of this vein imaging device to avoid accidental puncture of the vessels in facial injection of BTX-A and fillers to reduce bruising and to prevent intravascular injection and to consider the risk of external compression by fillers in high-risk zones for vascular occlusion, such as the glabella and the nasal wing.7

The device has been used in two ways: direct use during the injection process (Figures 1 and 2) and using the device to map the vessels before the pro-

Figure 1. Direct use of near-infrared device during botulinum toxin injection for periorbital rhytids.
Conclusion

The use of this technology in our patients should reduce the incidence of secondary effects (mainly hematoma), help to prevent serious complications such as vascular occlusion, and improve results of minimally invasive facial treatments such as BTX-A and fillers injections.

References


Address correspondence and reprint requests to: Guillermo Blugerman, MD, Centro B & S Excelencia en Cirugía Plástica, Laprida 1579, Buenos Aires, Argentina, or e-mail: blugerman@centrosbys.com